Jazz Pharmaceuticals (JAZZ) receives a BUY rating, driven by strong DUET trial results for Xywav in narcolepsy and idiopathic ...
The iShares MSCI Brazil ETF is rated a "Buy," offering strong performance, value sectors, and a high yield. Learn more about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback